

# **CANCER IN IDAHO – 2008 Preliminary**

**December 2009**

**A Publication of the  
Cancer Data Registry of Idaho**



**Editors:**

Christopher J. Johnson, MPH, Epidemiologist  
Stacey L. Carson, RHIT, CTR, Vice President Operations and Registry Services

**Contributors:**

Denise Jozwik, RHIT, CTR, Director  
Maryann Sacks, RHIT, CTR, Cancer Data Controller  
Loretta E. Travers, RHIT, CTR, Cancer Data Controller

---

CANCER DATA REGISTRY OF IDAHO  
P.O. Box 1278  
Boise, Idaho 83701-1278  
208-338-5100 ext 213 (phone)  
208-344-0180 (FAX)  
<http://www.idcancer.org>



IDAHO DEPARTMENT OF  
HEALTH & WELFARE

## **PREFACE**

"*Cancer in Idaho - 2008*," the thirty-second annual report of the Cancer Data Registry of Idaho (CDRI), contains data on cancer cases diagnosed during 2008 among Idaho residents. These data can be used by public health officials, hospital administrators, physicians, the Comprehensive Cancer Alliance for Idaho, and others to effectively plan services, prioritize health resource allocations, develop and measure prevention and intervention strategies, and identify high risk populations within the state of Idaho.

## **ACKNOWLEDGMENTS**

The Idaho Hospital Association (IHA) contracts with, and receives funding from, the Idaho Department of Health and Welfare, Division of Health, to provide a statewide cancer surveillance system.

The statewide cancer registry database is a product of collaboration among many report sources, including hospitals, physicians, surgery centers, pathology laboratories, and other states in which Idaho residents are diagnosed and/or treated for cancer. Their cooperation in reporting timely, accurate, and complete cancer data is acknowledged and sincerely appreciated.

CDRI would also like to thank the Division of Health, Idaho Department of Health and Welfare, and the Comprehensive Cancer Alliance for Idaho for their continued partnership and for using CDRI data as a tool in cancer control and prevention.

We acknowledge the Centers for Disease Control and Prevention, for its support of CDRI, and the printing and distribution of *Cancer in Idaho - 2008* under cooperative agreement 5U58DP000767-03 awarded to CDRI. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

## **SUGGESTED CITATION:**

Johnson CJ, Carson SL. *Cancer in Idaho, 2008, Preliminary Data*. Boise, ID: Cancer Data Registry of Idaho; December 2009.

## **COPYRIGHT INFORMATION:**

All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.

# Introduction to the Cancer Data Registry of Idaho (CDRI)

## Purpose of the Registry

Population-based cancer registries are essential for assessing the extent of cancer burden in a specified geographic area. The Cancer Data Registry of Idaho (CDRI) is a population-based cancer registry that collects incidence and survival data on all cancer patients who reside in the state of Idaho or who are diagnosed and/or treated for cancer in the state of Idaho. The goals of the CDRI are to:

- ◆ determine the incidence of cancer in the state of Idaho with respect to geographic, demographic, and social characteristics;
- ◆ monitor trends and patterns of cancer incidence over time;
- ◆ identify high risk populations;
- ◆ provide a database and serve as a resource in conducting epidemiologic studies; and
- ◆ provide data to assist public health officials, hospital administrators, and physicians to effectively plan services, prioritize health resource allocations and develop and measure prevention and intervention strategies.

## History and Funding of the Registry

CDRI was established in 1969 and became population-based in 1971. The Idaho State Legislature has provided guidelines for the establishment, requirements, and funding of the statewide cancer registry. The operations of the registry are mandated by Idaho Code 57-1703 through 57-1707. Funding is appropriated in Idaho Code 57-1701 and 63-2520, which delineates a portion (less than one percent) of the cigarette tax to be dedicated to fund the statewide cancer registry. Through the National Program of Cancer Registries (NPCR), additional funding has been awarded to CDRI from the Centers for Disease Control and Prevention (CDC) to

enhance timely, complete and accurate data collection, computerization, and reporting of reliable data.

## Collection of Data

Each Idaho hospital, outpatient surgery center, and pathology laboratory is responsible for the complete ascertainment of all data on cancer diagnoses and treatments provided in its facility within six months of diagnosis. Sources for identifying eligible cases include:

- ◆ hospitals,
- ◆ outpatient surgery centers,
- ◆ private pathology laboratories,
- ◆ free-standing radiation centers,
- ◆ physicians (for patients not receiving cancer diagnoses and/or treatment in the above sources),
- ◆ death certificates, and
- ◆ other state cancer registries reporting an Idaho resident with cancer (as negotiated).

Incomplete case reporting by US Veterans Affairs (VA) hospitals since late 2004 may have resulted in 40,000 to 70,000 cases being missed nationwide each year.<sup>1</sup> The impact of incomplete case reporting of VA cases on Idaho cancer statistics is unknown, but acknowledged.

When a cancer case is reported from more than one source, the information is consolidated into one record.

Reported cases contain the following data:

- ◆ patient demographics (including geographic place of residence at time of cancer diagnosis);
- ◆ description of cancer (including date of diagnosis, primary site, metastatic sites, histology, extent of disease, etc.);

- ◆ first course treatment; and
- ◆ follow-up data for purposes of calculating survival rates.

Primary site, behavior, grade, and histology were coded according to the *International Classification of Diseases for Oncology, 3rd edition*.<sup>2</sup> Stage of disease variables were coded using SEER's *Summary Staging Manual 2000*, the *AJCC Manual for Staging of Cancer, 6th edition*, and the *Collaborative Staging Manual, Version 1.04*.<sup>3,4,5</sup> SEER Summary Stage was derived from Collaborative Staging variables. All other variables were coded following the rules of the North American Association of Central Cancer Registries (NAACCR), the National Cancer Institute's SEER program, and the American College of Surgeons Commission on Cancer.<sup>6-8</sup> Beginning with cases diagnosed in 2007, new rules for coding multiple primaries and histologies were applied.<sup>9</sup> These rules standardize the process of determining the number of primary cases and provide guidance for identifying histologic lineages.

### **Reportable Cases**

All in-situ or malignant neoplasms are reportable to CDRI. The database includes all cases of carcinoma, sarcoma, melanoma, lymphoma, and leukemia, diagnosed by histology/cytology, radiology, laboratory testing, clinical observation, and autopsy.

Also reportable are benign and borderline behavior intracranial and central nervous system tumors.

Basal and squamous cell carcinomas of the skin are excluded except when occurring on a mucous membrane or if the AJCC stage group is II, III, or IV.

Under Idaho Code and as recommended by NAACCR, cervix in-situ cases are not currently reportable.

### **Confidentiality of Data**

Idaho state law ensures the protection of confidential data and restricts the release of identifying data. Only aggregate data are published. The same law protects report sources from any liability for reporting confidential data to CDRI. Persons with access to confidential data are required to sign a pledge of confidentiality and are subject to penalty if they, through negligence or willful misconduct, disclose confidential data.

### **Quality Assurance**

To assure validity and reliability of data presented, CDRI has many mechanisms in place to check data for quality and completeness. CDRI uses EDITS software which has standard edits using algorithms that check the content of data fields against an encoded set of acceptable possible contents and flags the acceptability of coded data. Edits include field edits, inter-field edits, and inter-record edits. Edits check for unlikely sex/site, site/histology and site/age combinations. In addition to computerized edits, cases are manually reviewed for errors.

Records are also routinely checked for duplicate entries. Duplicate case checking is performed both manually and electronically using several methodologies.

CDRI has met NPCR program standards and is recognized as a "gold standard registry" for quality, completeness and timeliness as designated by NAACCR. These designations enable Idaho data to be included in *United States Cancer Statistics* and all NAACCR volumes of *"Cancer Incidence in North America."*

### 2008 Idaho Cancer Incidence Rates by Sex (Preliminary)

Primary Site	Total			Male			Female		
	Rate	Cases	Pop	Rate	Cases	Pop	Rate	Cases	Pop
All Sites	451.1	6,876	1,523,816	504.1	3,610	766,580	409.7	3,266	757,236
Bladder	21.7	328	1,523,816	37.6	258	766,580	8.5	70	757,236
Brain - malignant	7.3	113	1,523,816	8.9	67	766,580	5.8	46	757,236
Brain and other CNS - non-malignant	9.2	137	1,523,816	6.6	46	766,580	11.6	91	757,236
Breast	61.3	937	1,523,816	1.0	6	766,580	117.4	931	757,236
Breast - in situ	13.2	203	1,523,816	0.0	0	766,580	25.6	203	757,236
Cervix	3.1	45	1,523,816	0.0	0	766,580	6.2	45	757,236
Colorectal	39.4	602	1,523,816	42.3	301	766,580	36.5	301	757,236
Corpus Uteri	11.6	184	1,523,816	0.0	0	766,580	22.4	184	757,236
Esophagus	4.8	73	1,523,816	8.9	64	766,580	1.1	9	757,236
Hodgkin Lymphoma	3.3	50	1,523,816	3.6	27	766,580	3.1	23	757,236
Kidney and Renal Pelvis	13.5	206	1,523,816	17.0	121	766,580	10.3	85	757,236
Larynx	2.8	45	1,523,816	4.5	36	766,580	1.2	9	757,236
Leukemia	13.9	211	1,523,816	15.6	111	766,580	12.4	100	757,236
Liver and Bile Duct	4.5	73	1,523,816	6.9	54	766,580	2.2	19	757,236
Lung and Bronchus	55.5	840	1,523,816	64.7	449	766,580	48.5	391	757,236
Melanoma of the Skin	20.4	310	1,523,816	27.8	202	766,580	14.0	108	757,236
Myeloma	5.9	91	1,523,816	7.4	52	766,580	4.7	39	757,236
Non-Hodgkin Lymphoma	20.5	309	1,523,816	23.7	169	766,580	17.9	140	757,236
Oral Cavity and Pharynx	11.2	175	1,523,816	15.8	121	766,580	6.8	54	757,236
Ovary	6.2	93	1,523,816	0.0	0	766,580	11.7	93	757,236
Pancreas	10.7	163	1,523,816	11.0	78	766,580	10.4	85	757,236
Prostate	68.5	1059	1,523,816	145.5	1059	766,580	0.0	0	757,236
Stomach	5.3	79	1,523,816	6.1	42	766,580	4.5	37	757,236
Testis	3.1	46	1,523,816	6.1	46	766,580	0.0	0	757,236
Thyroid	17.2	254	1,523,816	7.6	57	766,580	26.7	197	757,236
Pediatric Age 0 to 19	16.9	77	456,189	16.4	38	233,191	17.6	39	222,998

Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) standard.

## 2008 Idaho Cancer Incidence Counts by Behavior (Preliminary)

Primary Site	In situ	Malignant
All Sites	706	6,692
Bladder	184	144
Brain	0	113
Breast	203	937
Cervix	0	45
Colorectal	12	602
Corpus Uteri	1	184
Esophagus	1	73
Hodgkin Lymphoma	0	50
Kidney and Renal Pelvis	5	206
Larynx	4	45
Leukemia	0	211
Liver and Bile Duct	0	73
Lung and Bronchus	1	840
Melanoma of the Skin	235	310
Myeloma	0	91
Non-Hodgkin Lymphoma	0	309
Oral Cavity and Pharynx	5	175
Ovary	0	93
Pancreas	1	163
Prostate	3	1,059
Stomach	0	79
Testis	0	46
Thyroid	0	254
Pediatric Age 0 to 19	3	77

**2008 Idaho Cancer Incidence Counts by SEER Summary Stage (Preliminary)**

Primary Site	In situ	Localized	Regional	Distant	Unstaged
All Sites	706	2,978	1,311	1,566	837
Bladder	184	96	24	11	13
Brain	0	81	18	3	11
Breast	202	576	285	45	32
Cervix	0	20	10	9	6
Colorectal	12	234	219	104	45
Corpus Uteri	1	120	33	15	16
Esophagus	1	8	32	15	18
Hodgkin Lymphoma	0	8	25	15	2
Kidney and Renal Pelvis	5	128	31	33	14
Larynx	4	25	8	9	3
Leukemia	0	0	0	191	20
Liver and Bile Duct	0	23	12	17	21
Lung and Bronchus	1	121	157	424	138
Melanoma of the Skin	236	243	27	20	19
Myeloma	0	5	0	76	10
Non-Hodgkin Lymphoma	0	67	41	168	33
Oral Cavity and Pharynx	5	59	72	25	19
Ovary	0	8	11	61	13
Pancreas	1	10	41	64	48
Prostate	3	800	102	36	121
Stomach	0	9	17	28	25
Testis	0	29	12	4	1
Thyroid	0	183	58	8	5
Pediatric Age 0 to 19	3	29	15	32	1

**2008 Idaho Cancer Incidence Rates by Age (Preliminary)**

Age at Diagnosis	Rate	Cases	Pop
00-04	15.6	19	121,746
05-09	9.7	11	113,859
10-14	16.5	18	109,216
15-19	26.0	29	111,368
20-24	52.9	55	104,057
25-29	55.8	64	114,788
30-34	96.7	95	98,229
35-39	128.9	126	97,722
40-44	203.1	194	95,508
45-49	318.9	337	105,692
50-54	517.0	530	102,514
55-59	794.0	730	91,945
60-64	1,093.0	820	75,022
65-69	1,748.8	980	56,040
70-74	2,098.8	875	41,691
75-79	2,340.0	776	33,163
80-84	2,372.4	611	25,755
85+	2,376.4	606	25,501

Rates are per 100,000.

### 2008 Idaho Cancer Mortality Rates by Sex (Final)

Cause of Death	Total			Male			Female		
	Rate	Deaths	Pop	Rate	Deaths	Pop	Rate	Deaths	Pop
All Causes of Death	719.2	10,931	1,523,816	822.4	5,522	766,580	630.4	5,409	757,236
All Malignant Cancers	165.7	2,503	1,523,816	191.0	1,308	766,580	147.5	1,195	757,236
Bladder	4.8	69	1,523,816	8.1	51	766,580	2.4	18	757,236
Brain and Other Nervous System	4.8	73	1,523,816	5.3	39	766,580	4.3	34	757,236
Breast	11.8	180	1,523,816	0.5	3	766,580	21.8	177	757,236
Cervix	1.4	21	1,523,816	0.0	0	766,580	2.7	21	757,236
Colorectal	14.2	218	1,523,816	13.6	97	766,580	14.5	121	757,236
Corpus Uteri	1.8	27	1,523,816	0.0	0	766,580	3.4	27	757,236
Esophagus	4.8	72	1,523,816	8.0	58	766,580	1.8	14	757,236
Hodgkin Lymphoma	0.6	9	1,523,816	0.6	4	766,580	0.7	5	757,236
Kidney	4.0	61	1,523,816	5.3	38	766,580	2.9	23	757,236
Larynx	0.4	7	1,523,816	0.9	7	766,580	0.0	0	757,236
Leukemia	7.3	109	1,523,816	9.2	63	766,580	5.8	46	757,236
Liver and Bile Duct	3.6	56	1,523,816	5.8	42	766,580	1.7	14	757,236
Lung and Bronchus	42.1	633	1,523,816	48.4	336	766,580	37.1	297	757,236
Melanoma of the Skin	3.3	50	1,523,816	4.7	33	766,580	2.2	17	757,236
Myeloma	3.5	52	1,523,816	4.5	30	766,580	2.6	22	757,236
Non-Hodgkin Lymphoma	6.3	95	1,523,816	9.1	59	766,580	4.5	36	757,236
Oral Cavity and Pharynx	2.7	41	1,523,816	3.7	27	766,580	1.8	14	757,236
Ovary	4.6	69	1,523,816	0.0	0	766,580	8.6	69	757,236
Pancreas	10.2	155	1,523,816	11.6	82	766,580	8.9	73	757,236
Prostate	10.8	161	1,523,816	25.8	161	766,580	0.0	0	757,236
Stomach	3.5	51	1,523,816	4.3	28	766,580	2.8	23	757,236
Testis	0.1	1	1,523,816	0.1	1	766,580	0.0	0	757,236
Thyroid	0.6	10	1,523,816	0.1	1	766,580	1.1	9	757,236

Data source: Bureau of Vital Records and Health Statistics (BVRHS), Idaho Department of Health and Welfare, 2009. Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130) standard. Cause of death categories are based on SEER cause of death recodes (<http://seer.cancer.gov/codrecodes/>), which differ from official BVRHS cancer mortality categories. Death counts may differ from official BVRHS statistics due to late filings.

# REFERENCES

1. Furlow, B. *Accuracy of US cancer surveillance under threat*. The Lancet Oncology, Vol. 8 (Sep. 2007), pp. 762-763.
2. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin D, Whelan S. *International Classification of Diseases for Oncology*. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
3. Young JL Jr., Roffers SD, Reis LAG, Fritz AG, Hurlbut AA (eds). *SEER Summary Staging Manual – 2000: Codes and Coding Instructions*. National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.
4. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (eds). *AJCC Cancer Staging Manual, Sixth Edition*. Chicago: American Joint Committee on Cancer; 2002.
5. Collaborative Staging Task Force of the American Joint Committee on Cancer. *Collaborative Staging Manual and Coding Instructions, Version 1.04.00*. Jointly published by American Joint Committee on Cancer (Chicago, IL) and U.S. Department of Health and Human Services (Bethesda, MD), 2004. NIH Publication Number 04-5496.
6. Havener L, Thornton M (eds). *Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Thirteenth Edition, Version 11.3*. Springfield, IL: North American Association of Central Cancer Registries, April 2008.
7. Cunningham J, Hankey B, Lyles B, Percy C, Ries L, Seiffert J, Shambaugh E, Van Holten V (eds). *SEER Program Code Manual*, rev. ed., Cancer Statistics Branch, National Cancer Institute; 1992.
8. Phillips JL, Stewart A, Tary P (eds). *Facility Oncology Registry Data Standards (FORDS)*. Chicago, IL: American College of Surgeons, Commission on Cancer, 2004 revision.
9. Johnson CH, Peace S, Adamo P, Fritz A, Percy-Laurry A, Edwards BK. *The 2007 Multiple Primary and Histology Coding Rules*. National Cancer Institute, Surveillance, Epidemiology and End Results Program. Bethesda, MD, 2007.
10. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2005 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2009. Available at: [www.cdc.gov/uscs](http://www.cdc.gov/uscs).
11. Johnson CJ, Carson SL. *Cancer in Idaho by Race and Ethnicity: 1990-2001*. Boise, ID: Cancer Data Registry of Idaho; October 2003. Available on the web at [www.idcancer.org](http://www.idcancer.org) in the Special Reports section: <http://www.idcancer.org/special/Cancer%20in%20Idaho%20by%20Race%20and%20Ethnicity%201990%20to%202001.pdf>.
12. National Center for Health Statistics. Postcensal estimates of the resident population of the United States for July 1, 2000-July 1, 2008, by year, county, age, bridged race, Hispanic origin, and sex (Vintage 2008). Prepared under a collaborative arrangement with the U.S. Census Bureau; released May 14, 2009. Available from: <http://www.cdc.gov/nchs/about/major/dvs/popbridge/popbridge.htm> as of September 2, 2009
13. Schottenfeld D, Fraumeni JF Jr. (eds). *Cancer Epidemiology and Prevention*. New York: Oxford University Press; 1996.
14. Lenhard RE, Osteen RT, Gansler T (eds). *Clinical Oncology*. The American Cancer Society, Inc.: Atlanta; 2001.
15. Report on Carcinogens, Eleventh Edition; U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program; 2005.
16. Surveillance, Epidemiology, and End Results (SEER) Program ([www.seer.cancer.gov](http://www.seer.cancer.gov)) SEER\*Stat Database: Incidence - SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2008 Sub (2000-2006) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2006 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission.
17. DevCan: Probability of Developing or Dying of Cancer Software, Version 6.4.1; Statistical Research and Applications Branch, National Cancer Institute, 2005. <http://srab.cancer.gov/devcan>.
18. Joinpoint Regression Program, Version 3.3.1. April 2008. Statistical Research and Applications Branch, National Cancer Institute. <http://srab.cancer.gov/joinpoint>.
19. Final 2007 mortality data, Bureau of Vital Records and Health Statistics, Idaho Department of Health and Welfare; November 2008.
20. Havener L (Ed). *Standards for Cancer Registries Volume III: Standards for Completeness, Quality, Analysis, and Management of Data*. Springfield (IL): North American Association of Central Cancer Registries, October 2004.

## APPENDIX A

### STANDARD SITE ANALYSIS CATEGORIES

SITE CATEGORY	PRIMARY SITE CODE
Categories in SMALL CAPITALS are aggregated from groups indented under them	EXCLUDES histologic types 9590-9989
<b>ORAL CAVITY &amp; PHARYNX</b>	
Lip	C00.0 - C00.9
Tongue	C01.9 - C02.9
Salivary Glands	C07.9 - C08.9
Floor of Mouth	C04.0 - C04.9
Gum and Other Mouth	C03.0 - C03.9 C05.0 - C05.9 C06.0 - C06.9
Nasopharynx	C11.0 - C11.9
Tonsil	C09.0 - C09.9
Oropharynx	C10.0 - C10.9
Hypopharynx	C12.9 C13.0 - C13.9
Other Oral Cavity and Pharynx	C14.0 C14.2 - C14.8
<b>DIGESTIVE SYSTEM</b>	
Esophagus	C15.0 - C15.9
Stomach	C16.0 - C16.9
Small Intestine	C17.0 - C17.9
<b>COLON (Excluding Rectum)</b>	
Cecum	C18.0
Appendix	C18.1
Ascending Colon	C18.2
Hepatic Flexure	C18.3
Transverse Colon	C18.4
Splenic Flexure	C18.5
Descending Colon	C18.6
Sigmoid Colon	C18.7
Large Intestine, NOS	C18.8 – C18.9, C26.0

SITE CATEGORY Categories in SMALL CAPITALS are aggregated from the groups indented under them	PRIMARY SITE CODE EXCLUDES histologic types 9590-9989
<b>RECTUM AND RECTOSIGMOID</b>	
Rectosigmoid Junction	C19.9
Rectum	C20.9
Anus, Anal Canal, & Anorectum	C21.0 - C21.2 C21.8
Liver	C22.0
Intrahepatic Bile Duct	C22.1
Gallbladder	C23.9
Other Biliary	C24.0 - C24.9
Pancreas	C25.0 – C25.9
Retroperitoneum	C48.0
Peritoneum, Omentum, & Mesentery	C48.1 - C48.2
Other Digestive Organs	C26.8 – C26.9 C48.8
<b>RESPIRATORY SYSTEM</b>	
Nasal Cavity, Middle Ear, & Accessory Sinuses	C30.0 - C30.1 C31.0 - C31.9
Larynx	C32.0 - C32.9
Lung and Bronchus	C34.0 – C34.9
Pleura	C38.4
Trachea, Mediastinum, & Other Respiratory Organs	C33.9 C38.1 - C38.3 C38.8 C39.0 C39.8 C39.9
<b>BONES AND JOINTS</b>	C40.0 – C41.9
<b>SOFT TISSUE (Including Heart)</b>	C38.0 C47.0 – C47.9 C49.0 – C49.9

<b>SITE CATEGORY</b>	<b>PRIMARY SITE CODE</b>
Categories in SMALL CAPITALS are aggregated from the groups indented under them	EXCLUDES histologic types 9590-9989
<b>SKIN (Excluding Basal and Squamous)</b>	
Melanomas - Skin	C44.0 – C44.9 Histology Types 8720 - 8790 ONLY
Other Non - Epithelial	C44.0 – C44.9 Also Excluding Histology Types 8000 – 8004 8010 – 8045 8050 – 8082 8090 – 8110 8720 – 8790 9590 – 9989
<b>BREAST</b>	C50.0 – C50.9
<b>FEMALE GENITAL SYSTEM</b>	
Cervix Uteri	C53.0 – C53.9
Corpus Uteri	C54.0 – C54.9
Uterus, NOS	C55.9
Ovary	C56.9
Vagina	C52.9
Vulva	C51.0 – C51.9
Other Female Genital Organs	C57.0 – C58.9
<b>MALE GENITAL SYSTEM</b>	
Prostate	C61.9
Testis	C62.0 – C62.9
Penis	C60.0 – C60.9
Other Male Genital Organs	C63.0 – C63.9
<b>URINARY SYSTEM</b>	
Bladder	C67.0 – C67.9
Kidney and Renal Pelvis	C64.9 C65.9
Ureter	C66.9
Other Urinary Organs	C68.0 – C68.9
<b>EYE AND ORBIT</b>	C69.0 – C69.9

SITE CATEGORY Categories in SMALL CAPITALS are aggregated from the groups indented under them	PRIMARY SITE CODE EXCLUDES histologic types 9590-9989
<b>BRAIN AND OTHER NERVOUS SYSTEM</b>	
Brain	C71.0 – C71.9 Also excludes: 9530 - 9539 And 9590 – 9989
Other Nervous System	A) C71.0 – C71.9 (meningioma) Histologic Type: 9530- 9539 ONLY B) C70.0 - C70.9 C) C72.0 - C72.9
<b>ENDOCRINE SYSTEM</b>	
Thyroid	C73.9
Other Endocrine (Including Thymus )	C37.9 C74.0 - C74.9 C75.0 - C75.9

SITE CATEGORY	PRIMARY SITE CODE	HISTOLOGY
Categories in SMALL CAPITALS are aggregated from the groups indented under them		
LYMPHOMAS		
Hodgkin Lymphoma		
Nodal	C02.4, C09.8, C09.9, C11.1, C14.2, C37.9 C42.2 C77.0 - C77.9	Types: 9650 - 9667 ONLY
Extranodal	For All Other Sites Exclude Sites: C02.4, C09.8, C09.9, C11.1, C14.2, C37.9, C42.2 C77.0 - C77.9	Types: 9650 - 9667 ONLY
Non - Hodgkin Lymphoma		
Nodal	C02.4, C09.8, C09.9, C11.1, C14.2, C37.9, C42.2 C77.0 - C77.9	Types: 9590 - 9596 9670 - 9729, 9823, 9827 ONLY
Extranodal	For All Other Sites Excluding Sites: C02.4, C09.8, C09.9, C11.1, C14.2, C37.9, C42.2 C77.0 - C77.9	Types: 9590 - 9595 9670 - 9729 ONLY  Types: 9823, 9827 For All Other Sites Except C42.0, C42.1, C42.4
MULTIPLE MYELOMA	For All Sites	Types: 9731 - 9732 ONLY

SITE CATEGORY	HISTOLOGY
Categories in SMALL CAPITALS are aggregated from the groups indented under them	
LEUKEMIAS	
Lymphocytic	
Acute Lymphocytic	Type: 9821, 9828, ONLY
Chronic Lymphocytic	Type: 9823 ONLY
Other Lymphocytic	Type: 9820, 9822, 9824, 9825, 9826, ONLY
Granulocytic (Myeloid)	
Acute Granulocytic	Type: 9840, 9861, 9866, 9867, 9871 - 9874 ONLY
Chronic Granulocytic	Type: 9863, 9868, ONLY
Other Granulocytic	Type: 9860, 9862, 9864, ONLY
Monocytic	
Acute Monocytic	Type: 9891 ONLY
Chronic Monocytic	Type: 9893 ONLY
Other Monocytic	Type: 9890, 9892, 9894, ONLY
Other	
Other Acute	Type: 9801, 9841, 9931, 9932 ONLY
Other Chronic	Type: 9803, 9842 ONLY
Aleukemic, Subleukemic, & NOS	Type: 9800, 9802, 9804, 9830, 9850, 9870, 9880, 9900, 9910, 9930, 9940, 9941 ONLY Type 9827 For Sites C42.0, C42.1, C42.4 ONLY

SITE CATEGORY	PRIMARY SITE CODE
Categories in SMALL CAPITALS are aggregated from the groups indented under them  ILL- DEFINED AND UNSPECIFIED SITES	EXCLUDES histologic types 9590-9989  A) Type: 9720 - 9723 9740 9741 9760 - 9764 9950 - 9989 ONLY For All Sites B) C76.0 - C76.8 C80.9 Type: 8000 - 9589 C) C42.0 - C42.4 Type 8000 - 9589 D) C77.0 - C77.9 Type 8000 - 9589
INVALID SITE	Site or histology code not within valid range or site code not found in this table.

Source: "Standards for Completeness, Quality, Analysis, and Management of Data, Vol III". North American Association of Central Cancer Registries, October 2004.<sup>20</sup>

## APPENDIX B

### 2000 U.S. STANDARD POPULATION

Age Group	2000 US Standard Population (Census P25-1130)
0	3,794,901
1-4	15,191,619
5-9	19,919,840
10-14	20,056,779
15-19	19,819,518
20-24	18,257,225
25-29	17,722,067
30-34	19,511,370
35-39	22,179,956
40-44	22,479,229
45-49	19,805,793
50-54	17,224,359
55-59	13,307,234
60-64	10,654,272
65-69	9,409,940
70-74	8,725,574
75-79	7,414,559
80-84	4,900,234
85+	4,259,173
Total	274,633,642

Source: SEER Program, National Cancer Institute, 2008.<sup>16</sup>

## APPENDIX C

### 2008 POPULATION BY HEALTH DISTRICT, GENDER, AND AGE GROUP

	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	STATE
<b>Males</b>								
< 5	6,585	2,911	2,830	16,751	7,600	7,316	9,826	62,360
5 to 9	6,943	2,880	2,778	16,030	6,753	6,822	7,989	58,161
10 to 14	7,284	2,976	2,866	15,592	6,456	6,461	7,335	56,187
15 to 19	7,423	4,295	4,146	14,388	6,649	6,469	8,234	56,483
20 to 24	6,224	5,434	5,269	14,839	5,742	6,573	9,057	55,562
25 to 29	7,677	3,695	3,589	17,138	6,543	6,497	7,969	59,845
30 to 34	6,244	2,888	2,736	15,879	5,539	4,604	5,673	50,024
35 to 39	6,473	2,867	2,651	17,294	5,222	4,427	5,095	49,841
40 to 44	6,651	2,951	2,741	15,813	5,522	4,384	5,353	48,251
45 to 49	7,651	3,484	3,249	15,915	6,272	5,457	6,301	52,895
50 to 54	7,725	3,639	3,472	14,764	6,101	5,549	6,041	50,838
55 to 59	7,615	3,481	3,272	12,666	5,258	4,990	5,396	45,697
60 to 64	6,345	2,952	2,771	10,178	4,510	3,861	4,276	37,356
65 to 69	4,849	2,333	2,147	6,903	3,400	2,828	3,203	27,721
70 to 74	3,705	1,804	1,654	4,685	2,528	2,061	2,172	20,097
75 to 79	2,745	1,433	1,342	3,399	1,957	1,611	1,602	15,103
80 to 84	1,885	1,081	1,002	2,376	1,501	1,190	1,129	10,916
85+	1,494	966	905	1,882	1,446	853	889	9,243
<b>Total</b>	<b>105,518</b>	<b>52,070</b>	<b>49,420</b>	<b>216,492</b>	<b>88,999</b>	<b>81,953</b>	<b>97,540</b>	<b>766,580</b>
<b>Females</b>								
< 5	6,243	2,806	2,744	15,899	7,120	7,186	9,237	59,386
5 to 9	6,867	2,733	2,663	15,504	6,419	6,431	7,563	55,698
10 to 14	6,836	2,746	2,628	14,721	6,202	6,142	6,921	53,029
15 to 19	6,722	3,874	3,757	13,426	6,213	6,401	9,921	54,885
20 to 24	5,864	4,476	4,389	12,582	5,217	6,361	7,003	48,495
25 to 29	7,270	2,693	2,666	15,624	5,271	5,624	8,098	54,943
30 to 34	6,186	2,720	2,658	14,913	5,101	4,793	5,594	48,205
35 to 39	6,757	2,711	2,600	15,032	5,039	4,823	5,249	47,881
40 to 44	6,670	2,911	2,790	14,902	5,447	4,669	5,368	47,257
45 to 49	7,881	3,639	3,428	15,745	6,120	5,474	6,317	52,797
50 to 54	8,422	3,607	3,467	14,703	6,026	5,550	6,116	51,676
55 to 59	7,702	3,448	3,266	12,790	5,497	4,987	5,254	46,248
60 to 64	6,461	2,859	2,691	10,088	4,562	3,828	4,323	37,666
65 to 69	4,860	2,375	2,224	7,083	3,487	2,873	3,206	28,319
70 to 74	3,664	1,823	1,681	5,321	2,829	2,227	2,201	21,594
75 to 79	2,989	1,629	1,529	4,231	2,470	1,901	1,933	18,060
80 to 84	2,506	1,380	1,299	3,452	2,054	1,459	1,510	14,839
85+	2,452	1,599	1,522	3,775	2,327	1,675	1,453	16,258
<b>Total</b>	<b>106,352</b>	<b>50,029</b>	<b>48,002</b>	<b>209,791</b>	<b>87,401</b>	<b>82,404</b>	<b>97,267</b>	<b>757,236</b>
<b>Total</b>	<b>211,870</b>	<b>102,099</b>	<b>97,422</b>	<b>426,283</b>	<b>176,400</b>	<b>164,357</b>	<b>194,807</b>	<b>1,523,816</b>

Source: National Center for Health Statistics, 2009.<sup>12</sup>